WS Investor
26 Feb 2025, 19:15
United Therapeutics Corporation reported record financial results for the fourth quarter and full year 2024, driven by strong sales growth across its product portfolio.
Key Financial Highlights
For the full year, revenue increased by 24% to $2.88 billion, compared to $2.33 billion in 2023. Net income rose 21% to $1.2 billion, with diluted earnings per share (EPS) at $24.64, up from $19.81 in 2023.
For the fourth quarter, revenue grew 20% year-over-year to $735.9 million, while net income surged 39% to $301.3 million. Diluted EPS for the quarter was $6.19, compared to $4.36 in Q4 2023.
Revenue Breakdown
The company's flagship Tyvaso franchise, used for pulmonary hypertension, continued its strong growth:
- Tyvaso DPI (inhaled dry powder) revenue grew 41% to $1.03 billion for the full year.
- Nebulized Tyvaso sales rose 17% to $586.8 million.
- Total Tyvaso sales increased 31% to $1.62 billion.
Other key products also saw robust performance:
- Remodulin, used for pulmonary arterial hypertension, grew 9% to $538.1 million.
- Orenitram, an oral prostacyclin analogue, increased 21% to $434.3 million.
- Unituxin, a pediatric neuroblastoma treatment, rose 20% to $238.7 million.
The company's U.S. market remains dominant, contributing $2.74 billion in revenue, while international markets brought in $137.7 million.
Operational Updates
- Research and development expenses totaled $481 million in 2024, up 18%, reflecting investments in TETON clinical trials for idiopathic pulmonary fibrosis and UKidney xenotransplantation studies.
- The company recorded a $71.1 million accrual for ongoing litigation with Sandoz Inc.
- United Therapeutics repurchased 3.5 million shares for $1 billion, reducing outstanding shares and supporting EPS growth.
Looking Ahead to 2025
CEO Martine Rothblatt highlighted an ambitious pipeline, including:
- TETON trial results for Tyvaso in pulmonary fibrosis, expected in the second half of 2025.
- Ralinepag, a once-daily prostacyclin agonist, with clinical data expected in 2026, positioned as a potential best-in-class treatment for pulmonary hypertension.
- FDA clearance for the first xenotransplantation study using UKidney, a potential breakthrough in organ transplantation.
United Therapeutics continues to deliver strong financial results, powered by record-breaking sales of Tyvaso and other core products. The company's strategic investments in research, clinical trials, and new treatment modalities position it for continued growth and innovation in 2025. A webcast discussing results will be held on February 26, 2025, at 9:00 a.m. ET.
Key Financial Highlights
For the full year, revenue increased by 24% to $2.88 billion, compared to $2.33 billion in 2023. Net income rose 21% to $1.2 billion, with diluted earnings per share (EPS) at $24.64, up from $19.81 in 2023.
For the fourth quarter, revenue grew 20% year-over-year to $735.9 million, while net income surged 39% to $301.3 million. Diluted EPS for the quarter was $6.19, compared to $4.36 in Q4 2023.
Revenue Breakdown
The company's flagship Tyvaso franchise, used for pulmonary hypertension, continued its strong growth:
- Tyvaso DPI (inhaled dry powder) revenue grew 41% to $1.03 billion for the full year.
- Nebulized Tyvaso sales rose 17% to $586.8 million.
- Total Tyvaso sales increased 31% to $1.62 billion.
Other key products also saw robust performance:
- Remodulin, used for pulmonary arterial hypertension, grew 9% to $538.1 million.
- Orenitram, an oral prostacyclin analogue, increased 21% to $434.3 million.
- Unituxin, a pediatric neuroblastoma treatment, rose 20% to $238.7 million.
The company's U.S. market remains dominant, contributing $2.74 billion in revenue, while international markets brought in $137.7 million.
Operational Updates
- Research and development expenses totaled $481 million in 2024, up 18%, reflecting investments in TETON clinical trials for idiopathic pulmonary fibrosis and UKidney xenotransplantation studies.
- The company recorded a $71.1 million accrual for ongoing litigation with Sandoz Inc.
- United Therapeutics repurchased 3.5 million shares for $1 billion, reducing outstanding shares and supporting EPS growth.
Looking Ahead to 2025
CEO Martine Rothblatt highlighted an ambitious pipeline, including:
- TETON trial results for Tyvaso in pulmonary fibrosis, expected in the second half of 2025.
- Ralinepag, a once-daily prostacyclin agonist, with clinical data expected in 2026, positioned as a potential best-in-class treatment for pulmonary hypertension.
- FDA clearance for the first xenotransplantation study using UKidney, a potential breakthrough in organ transplantation.
United Therapeutics continues to deliver strong financial results, powered by record-breaking sales of Tyvaso and other core products. The company's strategic investments in research, clinical trials, and new treatment modalities position it for continued growth and innovation in 2025. A webcast discussing results will be held on February 26, 2025, at 9:00 a.m. ET.
